Bibliography
- Abrams P, Cardozo L, Fall M, et al. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 2003;61(1):37-49
- Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary Incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50(6):1306-14
- Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20(6):327-36
- Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87(9):760-6
- de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 2006;147:S25-40
- de Groat WC. A neurologic basis for the overactive bladder. Urology 1997;50:36-52
- Brading AF. A myogenic basis for the overactive bladder. Urology 1997;50(6A Suppl):57-67
- Drake MJ, Mills IW, Gillespie JI. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 2001;358(9279):401-3
- Fowler CJ. Bladder afferents and their role in the overactive bladder. Urology 2002;59:37-42
- Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
- Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary Incontinence. Pharmacol Rev 2004;56:581-631
- Sacco E, Pinto F, Bassi P. Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:583-98
- Sigala S, Mirabella G, Peroni A, et al. Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology 2002;60:719-25
- Stevens LA, Chapple CR, Chess-Williams R. Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction. Eur Urol 2007;52:531-8
- Theravance Inc. Substituted 4-amino-1-(pyridylmethyl) piperidine as muscarinic receptor antagonists. MXPA05004507; 2005
- Theravance Inc. Substituted 4-amino-1 (pyridylmethyl) piperidine and related compounds. US2008091034; 2008
- Morita T, Iizuka H, Iwata T, Kondo S. Function and distribution of beta3-adrenoceptors in rat, rabbit and human urinary bladder and external urethral sphIncter. J Smooth Muscle Res 2000;36:21-32
- Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007;321:642-7
- Astellas Pharma Inc. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient. NZ539577; 2007
- Boehringer Ingelheim Int. Use of aminoalcohol derivatives for the treatment of overactive bladder. EP1965782; 2008
- Bayer Healthcare AG. 2-((2, 3-dihydroxypropyl) aminomethyl) chromane derivatives for use as beta-3 adrenoreceptor agonists in the treatment of urological and inflammatory disorders. CA2548922; 2005
- Nagy I, Sántha P, Jancsó G, Urbán L. The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. Eur J Pharmacol 2004;500:351-69
- Chancellor MB, de Groat WC .Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999;162:3-11
- Bayer Healthcare AG. Bicyclic amide, carbamate or urea derivatives as vanilloid receptor modulators. US2008058377; 2008
- Bayer Healthcare AG. Hydroxy-tetrahydro-naphthalenylurea derivatives. US2007027187; 2007
- Bayer Healthcare AG. Tetrahydro-quinolinylurea derivatives. US2007213363; 2007
- Bayer Healthcare AG. Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists. US2006135505; 2006
- Astrazeneca AB. Benzimidazole derivatives useful in treatment of vallinoid receptor TRPV1 related disorders. WO2008018827; 2008
- Astellas Pharma Inc. Benzamide derivative or salt thereof. US2007167444; 2007
- Wang X, Momota Y, Yanase H, et al. Urothelium EP1 receptor facilitates the micturition reflex in mice. Biomed Res 2008;29:105-11
- Cefalu JS, Zhu QM, Eggers AC, et al. Effects of the selective prostacyclin receptor antagonist RO3244019 on the micturition reflex in rats. J Urol 2007;178:2683-8
- Khera M, Boone TB, Salas N, et al. The role of the prostacyclin receptor antagonist RO3244019 in treating neurogenic detrusor overactivity after spinal cord injury in rats. BJU Int 2007;99:442-6
- Astellas Pharma INC. Carboxylic acid derivative or salt thereof. WO2007072782; 2007
- Astellas Pharma INC. Bicyclic heterocyclic derivative or salt thereof. WO2006121097; 2006
- Bayer Healthcare AG. 2-naphthamide derivatives. US2006166989; 2006
- Bayer Healthcare AG. Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists. US2006247260; 2006
- Bayer Healthcare AG. Carboxamides derivatives. US2006135613; 2006
- Bayer Healthcare AG. Phenyl or heteroaryl amino alkane derivatives as IP receptor antagonist. US2006089371; 2006
- Candenas L, Lecci A, Pinto FM, et al. Tachykinins and tachykinin receptors: effects in the genitourinary tract. Life Sci 2005;76:835-62
- Green SA, Alon A, Ianus J, et al. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary Incontinence. J Urol 2006;176:2535-40
- Glaxo Group Ltd. The use of 4-(S)-(4-acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxilic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide for the treatment of overactive bladder. EP1824487; 2007
- Pfizer. Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles. US2008132538; 2008
- Steers WD, Herschorn S, Kreder KJ, et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 2007;100:337-45
- Methods and compositions for the treatment of urinary Incontinence. US2008009538; 2008
- McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002;416:52-8
- Nagy I, Rang H. Noxious heat activates all capsaicin-sensitive and also a sub-population of capsaicin-insensitive dorsal root ganglion neurons. Neuroscience 1999;88:995-7
- Cesare P, McNaughton P. A novel heat-activated current in nociceptive neurons and its sensitization by bradykinin. Proc Natl Acad Sci USA 1996;93:15435-9
- Tsavaler L, Shapero MH, Morkowski S, et al. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 2001;61:3760-9
- Geirsson G, Fall M, Lindström S. The ice-water test–a simple and valuable supplement to routine cystometry. Br J Urol 1993;71:681-5
- Geirsson G, Fall M. The ice-water test in the diagnosis of detrusor-external sphIncter dyssynergia. Scand J Urol Nephrol 1995;29:457-61
- Chai TC, Gray ML, Steers WD. The Incidence of a positive ice water test in bladder outlet obstructed patients: evidence for bladder neural plasticity. J Urol 1998;160:34-8
- Bayer Healthcare AG. Substituted Benzyloxy-Phenylmethylamide Derivatives. WO2006040136; 2008
- Bayer Healthcare AG. Substituded benzyloxy-phenylmethylurea derivatives. WO2007080109; 2007
- Bayer Healthcare AG. Substituted benzyloxy-phenylmethylcarbamate derivatives. WO2007017094; 2007
- Black JA, Cummins TR, Yoshimura N, et al. Tetrodotoxin-resistant sodium channels Na(v)1.8/SNS and Na(v)1.9/NaN in afferent neurons innervating urinary bladder in control and spinal cord injured rats. Brain Res 2003;963:132-8
- Lenkowski PW, Ko SH, Anderson JD, et al. Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin. Eur J Pharm Sci 2004;21:635-44
- Univ Virginia. Compositions and methods for use of a sodium channel blocker. WO2007002885; 2007
- Dynogen Pharmaceuticals INC. Methods of using ziconotide to treat overactive bladder. US2006234939; 2006
- Dynogen Pharmaceuticals INC. Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators. US2006188575; 2006
- Dainippon Sumitomo Pharma Co. Hydroxyquinazolinone derivative. JP2008115118; 2008
- Mónica FZ, Bricola AA, Báu FR, et al. Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces beta(3)-adrenoceptor-mediated relaxation, causing rat detrusor overactivity. Br J Pharmacol 2008;153:1659-68
- Giannitsas K, Mitropoulos D, Konstantinopoulos A, et al. Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia. Expert Opin Pharmacother 2008;9:1687-93
- Aska Pharmaceutical Co LTD. Thienopyrimidine derivative. EP1908765; 2008
- Invest y Clinica Andrologicas. Use of PDE5 inhibitors for the treatment of overactive bladder. WO2007113243; 2007
- Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 2004;61:149-60
- Dmitrieva N, Berkley KJ. Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus. J Neuroscience 2002;22:7147-53
- Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003;9:76-81
- Astellas Pharma Inc. Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative. EP1849773; 2007
- Astellas Pharma INC. Urea compound or salt thereof. WO2008023720; 2008
- Kissei Pharmaceutical. Therapeutic agent for interstitial cystitis. CN101056627; 2007
- Toray industries. Arylmethylene urea derivative and use thereof. WO2007063868; 2007
- Kyowa Hakko. Kogyo KK. Medicinal composition. US2006160887; 2006
- Sculptoreanu A, Yoshimura N, de Groat WC. KW-7158 [(2S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide] enhances A-type K+ currents in neurons of the dorsal root ganglion of the adult rat. J Pharmacol Exp Ther 2004;310:159-68
- Szelenyi I, Nickel B. Putative site(s) and mechanism(s) of action of flupirtine, a novel analgesic compound. Postgrad Med J 1987;63:57-60
- Rupalla K, Cao W, Krieglstein J. Flupirtine protects neurons against excitotoxic or ischemic damage and inhibits the Increase in cytosolic Ca2+ concentration. Eur J Pharmacol 1995;294:469-73
- Kornhuber J, Bleich S, Wiltfang J, et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication. J Neural Transm 1999;106:857-67
- Elbion AG. The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome. CN101132793; 2008
- Chugai Pharmaceuticals Co. Ltd. Therapeutic agents for overactive bladder. US2008033018; 2008
- Kamiyama Y, Muto S, Masuda H, et al. Inhibitory effects of nicorandil, a K ATP channel opener and a nitric oxide donor, on overactive bladder in animal models. BJU Int 2008;101(3):360-5
- Muraki K, Sasaoka A, Watanabe M, Imaizumi Y. Effects of KRN2391 on ionic currents in rabbit femoral arterial myocytes. Br J Pharmacol 2001;132:1154-60
- Schmid DM, Roy S, Sulser T, et al. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity. BJU Int 2008;102(Suppl 1):7-10
- Giannantoni A, Mearini E, Del Zingaro M, et al. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application. BJU Int 2008;102:2-6
- Allergan Inc. Botulinum toxin compositions and methods. WO2008101098; 2008